69
nm Nanômetro
PAMP Padrão Molecular Associado à Patógenos PCR Reação em Cadeia da Polimerase
pH Potencial Hidrogeniônico RNA Ácido Ribonucleico RPM Rotações por Minuto SDB Sabouraud Dextrose Broth SNC Sistema Nervoso Central SyK Tirosina Quinase Esplênica Th Linfócito T Auxiliar TLR Receptor do Tipo toll TNF Fator de Necrose Tumoral O2 Oxigênio
UnB Universidade de Brasília USP Universidade de São Paulo WT Wild Type – Animal selvagem 6OHDA 6-hidroxidopamina
70
Referências
Adams JD Jr, Klaidman LK, Leung AC (1993) MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes. Free Radic Biol Med 15:181–186
Ahmet Unlu, Erdinc Nayir, Onder Kirca, Mustafa Ozdogan. Ganoderma Lucidum (Reishi Mushroom) and cancer. JBUON 2016; 21(4): 792-798
Ballester Ferré, M. P., Boscá-Watts, M. M., & Mínguez Pérez, M. (2018). Enfermedad de Crohn. Medicina Clínica, 151(1), 26–33. doi:10.1016/j.medcli.2017.10.036
Basso, A.M.M. Caracterização do potencial imunomodulador de polissacarídeos de basidiomicetos e aplicação em modelo de infecção fúngica experimental. Doutora (Doutorado em Patologia Molecular). 152 f. Universidade de Brasília – UnB. 2017
Becattini S, Taur Y, Pamer EG. Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends Mol Med. 2016;22(6):458–478. doi:10.1016/j.molmed.2016.04.003
Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients. Genome Med. 2017;9:39.
Bedarf, J.R., Hildebrand, F., Coelho, L.P. et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients. Genome Med 9, 39 (2017). https://doi.org/10.1186/s13073-017-0428-y
Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson’s disease. Bioessays 24:308–318
Borrello, S., Nicolò, C., Delogu, G., Pandolfi, F., & Ria, F. (2011). TLR2: A Crossroads between Infections and Autoimmunity? International Journal of Immunopathology and Pharmacology, 549–556
Burré J, Sharma M, Südhof TC. Cell Biology and Pathophysiology of α-Synuclein. Cold Spring Harb Perspect Med. 2018;8(3):a024091. Published 2018 Mar 1. doi:10.1101/cshperspect.a024091
Cash, H. L. (2006). Symbiotic Bacteria Direct Expression of an Intestinal Bactericidal Lectin. Science, 313(5790), 1126–1130. doi:10.1126/science.1127119
71 Chakravarthy, S., Balasubramani, P. P., Mandali, A., Jahanshahi, M., & Moustafa, A. A. (2018). The many facets of dopamine: Toward an integrative theory of the role of dopamine in managing the body’s energy resources. Physiology & Behavior, 195, 128–141. doi:10.1016/j.physbeh.2018.06.032
Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW. Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand. 1999;99:26-35.
Cleeter MW, Cooper JM, Schapira AH (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58:786– 789
Collins, F. L., Rios-Arce, N. D., Schepper, J. D., Parameswaran, N., & McCabe, L. R. (2017). The Potential of Probiotics as a Therapy for Osteoporosis. Microbiology Spectrum, 5(4). doi:10.1128/microbiolspec.bad-0015-2016
Crow, J. R., Davis, S. L., Chaykosky, D. M., Smith, T. T., & Smith, J. M. (2015). Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention ofClostridium difficileInfection. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 35(11), 1016–1025. doi:10.1002/phar.1644
Dalia Akramienė, Anatolijus Kondrotas, Janina Didžiapetrienė, Egidijus Kėvelaitis. Effects of b-glucans on the immune system. Medicina (Kaunas) 2007; 43(8)
Wagener M, Hoving JC, Ndlovu H, Marakalala MJ. Dectin-1-Syk-CARD9 Signaling Pathway in TB Immunity. Front Immunol. 2018;9:225. Published 2018 Feb 13. doi:10.3389/fimmu.2018.00225
de Clercq NC, Groen AK, Romijn JA, Nieuwdorp M. Gut Microbiota in Obesity and Undernutrition. Adv Nutr. 2016;7(6):1080–1089. Published 2016 Nov 15. doi:10.3945/an.116.012914
Duty, S., & Jenner, P. (2011). Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. British Journal of Pharmacology, 164(4), 1357– 1391. doi:10.1111/j.1476-5381.2011.01426.x
72 Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., … Bentivoglio, A. R. (2013). The role of small intestinal bacterial overgrowth in Parkinson’s disease. Movement Disorders, 28(9), 1241–1249. doi:10.1002/mds.25522
Ferri FF. Parkinson's disease. In: Ferri's Clinical Advisor 2018. Philadelphia, Pa.: Elsevier; 2018. https://www.clinicalkey.com. Accessed May 29, 2018.
Ford, A. C., Moayyedi, P., & Hanauer, S. B. (2013). Ulcerative colitis. BMJ, 346(feb05 2), f432–f432. doi:10.1136/bmj.f432
Freeman, H. J. (2014). Natural history and long-term clinical course of Crohn’s disease. World Journal of Gastroenterology, 20(1), 31. doi:10.3748/wjg.v20.i1.31
Fuss, M Neurath, M Boirivant, J S Klein, C de la Motte, S A Strong, C Fiocchi, W Strober. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.The Journal of Immunology August 1, 1996, 157 (3) 1261-1270;
Gallo, R.L., and Hooper, L.V. (2012). Epithelial antimicrobial defence of the skin and intestine. Nat. Rev. Immunol. 12, 503–516.
Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80–86. doi:10.1126/science.aaa4972
Gasbarrini, G., Bonvicini, F., & Gramenzi, A. (2016). Probiotics History. Journal of Clinical Gastroenterology, 50, S116–S119. doi:10.1097/mcg.0000000000000697
Geuking MB, Köller Y, Rupp S, McCoy KD. The interplay between the gut microbiota and the immune system. Gut Microbes. 2014;5(3):411–418. doi:10.4161/gmic.29330
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., … Hirayama, M. (2015). Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease. PLOS ONE, 10(11), e0142164. doi:10.1371/journal.pone.0142164
Hill-Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., … Payami, H. (2017). Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Movement Disorders, 32(5), 739–749. doi:10.1002/mds.26942
73 Hoffmann, C., Dollive, S., Grunberg, S., Chen, J., Li, H., Wu, G. D., … Bushman, F. D. (2013). Archaea and Fungi of the Human Gut Microbiome: Correlations with Diet and Bacterial Residents. PLoS ONE, 8(6), e66019. doi:10.1371/journal.pone.0066019
Hopfner F, Künstner A, Müller SH, Künzel S, Zeuner KE, Margraf NG, et al. Gut microbiota in Parkinson disease in a northern German cohort. Brain Res. 2017;1667:41–5.
Ianiro, G., Tilg, H., & Gasbarrini, A. (2016). Antibiotics as deep modulators of gut microbiota: between good and evil. Gut, 65(11), 1906–1915. doi:10.1136/gutjnl-2016-312297
Iliev ID. Dectin-1 Exerts Dual Control in the Gut. Cell Host Microbe. 2015;18(2):139–141. doi:10.1016/j.chom.2015.07.010
Iliev ID. Dectin-1 Exerts Dual Control in the Gut. Cell Host Microbe. 2015;18(2):139–141. doi:10.1016/j.chom.2015.07.010
Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79(4), 368–376. doi:10.1136/jnnp.2007.131045
Javitch JA, D’Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: uptake of the metabolite N- methyl-4- phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173–2177
Javitch JA, Snyder SH (1984) Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106:455–456
Javoy, F., Sotelo, C., Herbet, A., & Agid, Y. (1976). Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system. Brain Research, 102(2), 201–215. doi:10.1016/0006-8993(76)90877-5 Jayachandran M, Xiao J, Xu B. A Critical Review on Health Promoting Benefits of Edible Mushrooms through Gut Microbiota. Int J Mol Sci. 2017;18(9):1934. Published 2017 Sep 8. doi:10.3390/ijms18091934
Kathleen A. Head, ND, Julie S. Jurenka, MT. Inflammatory Bowel Disease Part I: Ulcerative Colitis – Pathophysiology and Conventional and Alternative Treatment Options. Alternative Medicine Review. 2003 Aug;8(3):247-83; PMID: 12946238
Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015;30:1351–60.
74 Kim S, Covington A, Pamer EG. The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. Immunol Rev. 2017;279(1):90–105. doi:10.1111/imr.12563
Klaidman LK, Adams JD Jr, Leung AC, Kim SS, Cadenas E (1993) Redox cycling of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic Biol Med 15:169–179
Langston JW. The MPTP Story. J Parkinsons Dis. 2017;7(s1):S11–S19. doi:10.3233/JPD- 179006
Lehotzky, R. E., Partch, C. L., Mukherjee, S., Cash, H. L., Goldman, W. E., Gardner, K. H., & Hooper, L. V. (2010). Molecular basis for peptidoglycan recognition by a bactericidal lectin. Proceedings of the National Academy of Sciences, 107(17), 7722–7727. doi:10.1073/pnas.0909449107
Li, D.Y., Tang, W.H.W. Gut Microbiota and Atherosclerosis. Curr Atheroscler Rep 19, 39 (2017).
Liu C, Dunkin D, Lai J, et al. Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-κB Signaling. Inflamm Bowel Dis. 2015;21(8):1918–1925. doi:10.1097/MIB.0000000000000439
Liu C, Dunkin D, Lai J, et al. Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-κB Signaling. Inflamm Bowel Dis. 2015;21(8):1918–1925. doi:10.1097/MIB.0000000000000439
Luo, J., Zhang, C., Liu, R., Gao, L., Ou, S., Liu, L., & Peng, X. (2018). Ganoderma lucidum polysaccharide alleviating colorectal cancer by alteration of special gut bacteria and regulation of gene expression of colonic epithelial cells. Journal of Functional Foods, 47, 127–135. doi:10.1016/j.jff.2018.05.041
Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65(2):330–339. doi:10.1136/gutjnl-2015-309990
Martin, C. R., & Mayer, E. A. (2017). Gut-Brain Axis and Behavior. Nestlé Nutrition Institute Workshop Series, 45–53. doi:10.1159/000461732
Mayer RA, Kindt MV, Heikkila RE (1986) Prevention of thenigrostriatal toxicity of 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem 47:1073–1079
75 Milani C, Duranti S, Bottacini F, et al. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. Microbiol Mol Biol Rev. 2017;81(4):e00036-17. Published 2017 Nov 8. doi:10.1128/MMBR.00036-17 Mizoguchi A, Yano A, Himuro H, Ezaki Y, Sadanaga T, Mizoguchi E. Clinical importance of IL-22 cascade in IBD. J Gastroenterol. 2018;53(4):465–474. doi:10.1007/s00535-017-1401-7 Mizuno Y, Sone N, Saitoh T (1987) Effects of 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J Neurochem 48:1787–1793
National Center for Biotechnology Information. PubChem Database. Dopamine, CID=681, https://pubchem.ncbi.nlm.nih.gov/compound/Dopamine (accessed on Jan. 24, 2020)
Neil A. R. Gow, Jean-Paul Latge, Carol A. Munro. The Fungal Cell Wall: Structure, Biosynthesis, and Function. microbiolspec May 2017 vol. 5 no. 3 doi:10.1128
Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4- phenyl1,2,5,6-tetrahydropyridine. Life Sci 36:2503–2508
Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE (1987) MPTP, MPP+ and mitochondrial function. Life Sci 40:721–729
Nishida, A., Inoue, R., Inatomi, O., Bamba, S., Naito, Y., & Andoh, A. (2017). Gut microbiota in the pathogenesis of inflammatory bowel disease. Clinical Journal of Gastroenterology, 11(1), 1–10. doi:10.1007/s12328-017-0813-5
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012). Ulcerative colitis. The Lancet, 380(9853), 1606–1619. doi:10.1016/s0140-6736(12)60150-0
OToole, P. W., & Jeffery, I. B. (2015). Gut microbiota and aging. Science, 350(6265), 1214– 1215. doi:10.1126/science.aac8469
Pagano G, Niccolini F, Politis M. Imaging in Parkinson's disease. Clin Med (Lond). 2016;16(4):371–375. doi:10.7861/clinmedicine.16-4-371
Pavlou, M. A. S., & Outeiro, T. F. (2017). Epigenetics in Parkinson’s Disease. Neuroepigenomics in Aging and Disease, 363–390. doi:10.1007/978-3-319-53889-1_19
76 Rai M., Tidke G., Wasser S.P. Therapeutic potential of mushrooms. Nat. Prod. Radiance. 2005;4:246–257.
Ramsay RR, Singer TP (1986) Energy-dependent uptake of Nmethyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 261:7585–7587
Rathee, Sushila, Rathee, Dharmender, Rathee, Deepti, Kumar, Vikash, & Rathee, Permender. (2012). Mushrooms as therapeutic agents. Revista Brasileira de Farmacognosia, 22(2), 459- 474. Epub October 21, 2011.https://dx.doi.org/10.1590/S0102-695X2011005000195
Reid, D. M., Gow, N. A., & Brown, G. D. (2009). Pattern recognition: recent insights from Dectin-1. Current Opinion in Immunology, 21(1), 30–37. doi:10.1016/j.coi.2009.01.003 Ren, J., Yuan, L., Wang, W., Zhang, M., Wang, Q., Li, S., … Hu, K. (2019). Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson’s disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway. Toxicology and Applied Pharmacology, 378, 114617. doi:10.1016/j.taap.2019.114617
Sampson TR, Debelius JW, Thron T, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016;167(6):1469–1480.e12. doi:10.1016/j.cell.2016.11.018
Sandhu, K. V., Sherwin, E., Schellekens, H., Stanton, C., Dinan, T. G., & Cryan, J. F. (2017). Feeding the microbiota-gut-brain axis: diet, microbiome, and neuropsychiatry. Translational Research, 179, 223–244. doi:10.1016/j.trsl.2016.10.002
Sands, B. E., & Kaplan, G. G. (2007). The Role of TNFα in Ulcerative Colitis. The Journal of Clinical Pharmacology, 47(8), 930–941. doi:10.1177/0091270007301623
Savchenko, A. S., Inoue, A., Ohashi, R., Jiang, S., Hasegawa, G., Tanaka, T., … Naito, M. (2011). Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathology International, 61(5), 290–297. doi:10.1111/j.1440- 1827.2011.02651.x
Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30:350–8.
Schober, A. (2004). Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP. Cell and Tissue Research, 318(1), 215–224. doi:10.1007/s00441-004-0938-y
77 Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010). Gut Microbiota in Health and Disease. Physiological Reviews, 90(3), 859–904.doi:10.1152/physrev.00045.2009
Shen, T.-C. D. (2017). Diet and Gut Microbiota in Health and Disease. Nestlé Nutrition Institute Workshop Series, 117–126. doi:10.1159/000455220
Shen, X., Yang, H., Wu, Y., Zhang, D., & Jiang, H. (2017). Meta-analysis: Association of Helicobacter pylori infection with Parkinson’s diseases. Helicobacter, 22(5), e12398. doi:10.1111/hel.12398
Sliva D, Loganathan J, Jiang J, et al. Mushroom Ganoderma lucidum prevents colitis-associated carcinogenesis in mice. PLoS One. 2012;7(10):e47873. doi:10.1371/journal.pone.0047873 Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., … Elinav, E. (2018). Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell, 174(6), 1406–1423.e16. doi:10.1016/j.cell.2018.08.047
Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118(2):534–544. doi:10.1172/JCI33194 Sun, M.-F., Zhu, Y.-L., Zhou, Z.-L., Jia, X.-B., Xu, Y.-D., Yang, Q., … Shen, Y.-Q. (2018). Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain, Behavior, and Immunity, 70, 48–60. doi:10.1016/j.bbi.2018.02.005
Tang, C., Kamiya, T., Liu, Y., Kadoki, M., Kakuta, S., Oshima, K., … Iwakura, Y. (2015). Inhibition of Dectin-1 Signaling Ameliorates Colitis by Inducing Lactobacillus-Mediated Regulatory T Cell Expansion in the Intestine. Cell Host & Microbe, 18(2), 183–197. doi:10.1016/j.chom.2015.07.003
Tarsy D. Pharmacologic treatment of Parkinson disease.
https://www.uptodate.com/contents/search. Accessed May 29, 2018.
Tatiya-aphiradee, N., Chatuphonprasert, W., & Jarukamjorn, K. (2018). Immune response and inflammatory pathway of ulcerative colitis. Journal of Basic and Clinical Physiology and Pharmacology, 0(0). doi:10.1515/jbcpp-2018-0036
Thiele SL, Warre R, Nash JE. Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease. J Vis Exp. 2012;(60):3234. Published 2012 Feb 14. doi:10.3791/3234
78 Tomkovich S, Jobin C. Microbiota and host immune responses: a love-hate relationship. Immunology. 2016;147(1):1–10. doi:10.1111/imm.12538
Torres-Fuentes, C., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2017). The microbiota–gut– brain axis in obesity. The Lancet Gastroenterology & Hepatology, 2(10), 747–756. doi:10.1016/s2468-1253(17)30147-4
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:10.1016/S0140-6736(16)32126-2
Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight RJ. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. Allergy Clin Immunol. 2012 May; 129(5):1204-8
Uyar GÖ, Yildiran H. A nutritional approach to microbiota in Parkinson's disease. Biosci Microbiota Food Health. 2019;38(4):115–127. doi:10.12938/bmfh.19-002
Vindigni, S. M., & Surawicz, C. M. (2017). Fecal Microbiota Transplantation. Gastroenterology Clinics of North America, 46(1), 171–185. doi:10.1016/j.gtc.2016.09.012 Wachtel-Galor S, Yuen J, Buswell JA, et al. Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 9.
Wagener, M., Hoving, J. C., Ndlovu, H., & Marakalala, M. J. (2018). Dectin-1-Syk-CARD9 Signaling Pathway in TB Immunity. Frontiers in Immunology, 9. doi:10.3389/fimmu.2018.00225
Wischmeyer, P. E., McDonald, D., & Knight, R. (2016). Role of the microbiome, probiotics, and “dysbiosis therapy” in critical illness. Current Opinion in Critical Care, 22(4), 347–353. doi:10.1097/mcc.0000000000000321
Xie J, Liu Y, Chen B, et al. Ganoderma lucidum polysaccharide improves rat DSS-induced colitis by altering cecal microbiota and gene expression of colonic epithelial cells. Food Nutr Res. 2019;63:10.29219/fnr.v63.1559. Published 2019 Feb 12. doi:10.29219/fnr.v63.1559 Xue, R., Zhang, H., Pan, J., Du, Z., Zhou, W., Zhang, Z., … Bai, L. (2018). Peripheral Dopamine Controlled by Gut Microbes Inhibits Invariant Natural Killer T Cell-Mediated Hepatitis. Frontiers in Immunology, 9. doi:10.3389/fimmu.2018.02398
79 Yoshitomi H, Sakaguchi N, Kobayashi K, et al. A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J
Exp Med. 2005;201(6):949–960. doi:10.1084/jem.20041758
Zhang, S.-L., Wang, S.-N., & Miao, C.-Y. (2017). Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention. Frontiers in Immunology, 8. doi:10.3389/fimmu.2017.01674